Asthma and COVID-19: In Defense of Evidence-Based SABA

There have recently been major objections to the use of short-acting beta-agonist (SABA) in episodic acute asthma culminating in a call for replacing SABA with combination of inhaled corticosteroids and long-acting beta-agonists despite little evidence supporting this point of view. It is regrettabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Amirav, Israel, Newhouse, Michael T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575826/
https://www.ncbi.nlm.nih.gov/pubmed/33116658
http://dx.doi.org/10.2147/JAA.S279061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575826/
https://www.ncbi.nlm.nih.gov/pubmed/33116658
http://dx.doi.org/10.2147/JAA.S279061

Ejemplares similares